Search Results - "Eitman, Cheryl"

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer by Brower, Blaine, McCoy, Asia, Ahmad, Hiba, Eitman, Cheryl, Bowman, I Alex, Rembisz, Jennifer, Milowsky, Matthew I

“…Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an…”
Get full text

Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype by Nelson, Ariel Ann, Wright, Matthew David, Khaki, Ali Raza, Diamantopoulos, Leonidas Nikolaos, Kyasaram, Ravi Kumar, Nezami, Behtash, Dawsey, Scott, Patel, Krupen, Eitman, Cheryl, MacLennan, Gregory, Grivas, Petros, Mendiratta, Prateek, Ponsky, Lee Evan, Hoimes, Christopher J.

“…Abstract only e16016 Background: Prior analyses demonstrated worse outcomes with the BP mUC clinical phenotype. UC molecular subtypes that may correlate with…”
Get full text

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188 by Hoimes, Christopher J., Adra, Nabil, Fleming, Mark T., Kaimakliotis, Hristos Z., Picus, Joel, Smith, Zachary L, Walling, Radhika, Trabulsi, Edouard John, Hoffman-Censits, Jean H., Koch, Michael O., Cary, Clint, Abouassaly, Robert, Eitman, Cheryl, Fu, Pingfu, Goolamier, Gordon, Calaway, Adam C, Ponsky, Lee Evan, Kelly, William Kevin

“…Abstract only 5047 Background: Patients (pts) with laUC who are C-eligible for N- therapy may benefit from combination chemo-immunotherapy. Cohort 1 (C1) of…”
Get full text

Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188 by Kaimakliotis, Hristos Z., Adra, Nabil, Kelly, William Kevin, Trabulsi, Edouard John, Lauer, Richard C., Picus, Joel, Smith, Zachary L, Walling, Radhika, Masterson, Timothy A., Calaway, Adam C, Koch, Michael O., Sonderman, Elizabeth, Fu, Pingfu, Goolamier, Gordon, Eitman, Cheryl, Ponsky, Lee Evan, Hoimes, Christopher J.

“…Abstract only 5019 Background: Patients (pts) with laUC who are C-ineligible have inferior survival compared to counterparts who receive C based N-therapy and…”
Get full text

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC) by Nelson, Ariel Ann, Opneja, Aman, Nezami, Behtash Ghazi, Ponsky, Lee Evan, Wright, Matthew David, Mergler, Patrick, Kyasaram, Ravi Kumar, Eitman, Cheryl, Patel, Krupen, MacLennan, Gregory, Cooney, Matthew M., Grivas, Petros, Barata, Pedro C., Garcia, Jorge A., Fu, Pingfu, Hoimes, Christopher J.

“…Abstract only…”
Get full text

Outcomes in bone predominant (BP) urothelial carcinoma (UC) by Nelson, Ariel Ann, Opneja, Aman, Nezami, Behtash Ghazi, Fu, Pingfu, Dawsey, Scott, Wright, Matthew David, Eitman, Cheryl, Kim, Simon P., Cooney, Matthew M., Grivas, Petros, MacLennan, Gregory, Hoimes, Christopher J.

“…Abstract only 441 Background: The clinical phenotype of BP UC includes those patients (pts) with at least as many or more bone lesions than non-bone lesions…”
Get full text

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC) by Hoimes, Christopher J., Abouassaly, Robert, Saltzman, Joel N., Fleming, Mark T., Hoffman-Censits, Jean H., Byrd, Tara, Eitman, Cheryl, Snyder-Willis, Michele, O'Neill, Jodi, Wood, Lisa, Elliott, Robin, Cooney, Matthew M.

“…Abstract only…”
Get full text